NasdaqCM - Delayed Quote USD

Greenwich LifeSciences, Inc. (GLSI)

12.34

-0.28

(-2.22%)

At close: April 25 at 4:00 PM EDT

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company's directors, officers, and existing pre-IPO investors to June 30, 2025 which is approximately 57 mont

GlobeNewswire last month
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

STAFFORD, Texas, March 12, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain. The Company has partnered with GEICAM, the largest academic breast cancer research network in Spa

GlobeNewswire last month
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been formally approved by Spain, France, Germany, Ital

GlobeNewswire last month
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

STAFFORD, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the expansion of the clinical trial into Europe. The Company's application to expand Flamingo-01 into Europe has been

GlobeNewswire 2 months ago
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

STAFFORD, Texas, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on the Phase III clinical trial, Flamingo-01. Data Safety Monitoring Board (DSMB) The Flamingo-01 DSMB met twice in 2023 and recommended to continue the study as is

GlobeNewswire 2 months ago
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced that its Board of Directors has extended the lock-up of the shares owned by the Company’s directors, officers, and existing pre-IPO investors to December 31, 2024 which is approximatel

GlobeNewswire 5 months ago

Performance Overview

Return	GLSI	S&P 500
YTD	+17.30%	+5.84%
1-Year	+10.08%	+22.03%
3-Year	-66.13%	+20.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Performance Overview